hrp0092lb-1 | Late Breaking Posters | ESPE2019
Horikawa Reiko
, Ogata Tsutomu
, Matsubara Yoichi
, Yokoya Susumu
, Ogawa Yoshihisa
, Nishijima Keiji
, Endo Takaaki
, Ozono Keiichi
Objectives: This trial (NCT01927861) evaluated the growth-promoting effect and safety of Norditropin® (somatropin; recombinant human growth hormone) in Japanese children with short stature due to Noonan syndrome over four years of treatment.Methods: Pre-pubertal children diagnosed with Noonan syndrome were randomized 1:1 to receive Norditropin® 0.033 mg/kg/day or 0.066 mg/kg/day. Change in...